Trial Outcomes & Findings for Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia (NCT NCT01865617)
NCT ID: NCT01865617
Last Updated: 2022-05-25
Results Overview
Death within 8 weeks of the study cell infusion thought to be definitely or probably related to CAR T cell therapy will be assessed.
Recruitment status
COMPLETED
Study phase
PHASE1/PHASE2
Target enrollment
204 participants
Primary outcome timeframe
Within 8 weeks of the study cell infusion
Results posted on
2022-05-25
Participant Flow
204 patients were enrolled on this study but only 197 met eligibility criteria and went on to be treated on study.
Participant milestones
| Measure |
ALL (High Tumor Burden) Dose Level 1
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: high Dose level: 1 up to 2x105 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
ALL (High Tumor Burden) Dose Level 2
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: high Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
ALL (High Tumor Burden) Dose Level 3
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: high Dose level: 3 up to 2x107 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
ALL (Low Tumor Burden) Dose Level 1
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: low Dose level: 1 up to 2x105 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
ALL (Low Tumor Burden) Dose Level 2
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: high Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
CLL Dose Level 1
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: CLL Dose level: 1 up to 2x105 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
CLL Dose Level 2
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: CLL Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
CLL Dose Level 3
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: CLL Dose level: 3 up to 2x107 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
CLL (Ibrutinib) Dose Level 2
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: CLL (ibrutinib) Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
NHL Dose Level 1
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: NHL Dose level: 1 up to 2x105 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
NHL Dose Level 2
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: NHL Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
NHL Dose Level 3
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: NHL Dose level: 3 up to 2x107 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
NHL (Dose Dense) Dose Level 2
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: NHL Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Study
STARTED
|
39
|
5
|
2
|
1
|
18
|
5
|
22
|
1
|
20
|
5
|
49
|
10
|
20
|
|
Overall Study
COMPLETED
|
9
|
2
|
1
|
0
|
11
|
4
|
10
|
0
|
9
|
2
|
17
|
4
|
7
|
|
Overall Study
NOT COMPLETED
|
30
|
3
|
1
|
1
|
7
|
1
|
12
|
1
|
11
|
3
|
32
|
6
|
13
|
Reasons for withdrawal
| Measure |
ALL (High Tumor Burden) Dose Level 1
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: high Dose level: 1 up to 2x105 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
ALL (High Tumor Burden) Dose Level 2
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: high Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
ALL (High Tumor Burden) Dose Level 3
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: high Dose level: 3 up to 2x107 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
ALL (Low Tumor Burden) Dose Level 1
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: low Dose level: 1 up to 2x105 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
ALL (Low Tumor Burden) Dose Level 2
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: high Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
CLL Dose Level 1
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: CLL Dose level: 1 up to 2x105 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
CLL Dose Level 2
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: CLL Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
CLL Dose Level 3
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: CLL Dose level: 3 up to 2x107 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
CLL (Ibrutinib) Dose Level 2
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: CLL (ibrutinib) Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
NHL Dose Level 1
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: NHL Dose level: 1 up to 2x105 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
NHL Dose Level 2
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: NHL Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
NHL Dose Level 3
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: NHL Dose level: 3 up to 2x107 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
NHL (Dose Dense) Dose Level 2
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: NHL Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Study
Death
|
27
|
3
|
1
|
1
|
5
|
1
|
11
|
1
|
11
|
3
|
32
|
6
|
13
|
|
Overall Study
Lost to Follow-up
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Overall Study
Withdrawal by Subject
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Overall Study
Patient proceeded to new therapy
|
0
|
0
|
0
|
0
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Overall Study
Other
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
Baseline Characteristics
Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia
Baseline characteristics by cohort
| Measure |
ALL (High Tumor Burden) Dose Level 1
n=39 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: high Dose level: 1 up to 2x105 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
ALL (High Tumor Burden) Dose Level 2
n=5 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: high Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
ALL (High Tumor Burden) Dose Level 3
n=2 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: high Dose level: 3 up to 2x107 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
ALL (Low Tumor Burden) Dose Level 1
n=1 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: low Dose level: 1 up to 2x105 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
ALL (Low Tumor Burden) Dose Level 2
n=18 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: high Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
CLL Dose Level 1
n=5 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: CLL Dose level: 1 up to 2x105 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
CLL Dose Level 2
n=22 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: CLL Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
CLL Dose Level 3
n=1 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: CLL Dose level: 3 up to 2x107 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
CLL (Ibrutinib) Dose Level 2
n=20 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: CLL (ibrutinib) Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
NHL Dose Level 1
n=5 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: NHL Dose level: 1 up to 2x105 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
NHL Dose Level 2
n=49 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: NHL Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
NHL Dose Level 3
n=10 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: NHL Dose level: 3 up to 2x107 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
NHL (Dose Dense) Dose Level 2
n=20 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: NHL Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
Total
n=197 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=30 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=114 Participants
|
0 Participants
|
0 Participants
n=19 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=7 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
35 Participants
n=99 Participants
|
5 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
1 Participants
n=7 Participants
|
15 Participants
n=31 Participants
|
4 Participants
n=30 Participants
|
17 Participants
n=3 Participants
|
1 Participants
n=6 Participants
|
12 Participants
n=114 Participants
|
4 Participants
|
40 Participants
n=19 Participants
|
8 Participants
n=4 Participants
|
15 Participants
n=7 Participants
|
158 Participants
n=7 Participants
|
|
Age, Categorical
>=65 years
|
4 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
3 Participants
n=31 Participants
|
1 Participants
n=30 Participants
|
5 Participants
n=3 Participants
|
0 Participants
n=6 Participants
|
8 Participants
n=114 Participants
|
1 Participants
|
9 Participants
n=19 Participants
|
2 Participants
n=4 Participants
|
5 Participants
n=7 Participants
|
39 Participants
n=7 Participants
|
|
Sex: Female, Male
Female
|
16 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
2 Participants
n=206 Participants
|
1 Participants
n=7 Participants
|
8 Participants
n=31 Participants
|
2 Participants
n=30 Participants
|
7 Participants
n=3 Participants
|
0 Participants
n=6 Participants
|
6 Participants
n=114 Participants
|
2 Participants
|
13 Participants
n=19 Participants
|
2 Participants
n=4 Participants
|
5 Participants
n=7 Participants
|
66 Participants
n=7 Participants
|
|
Sex: Female, Male
Male
|
23 Participants
n=99 Participants
|
3 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
10 Participants
n=31 Participants
|
3 Participants
n=30 Participants
|
15 Participants
n=3 Participants
|
1 Participants
n=6 Participants
|
14 Participants
n=114 Participants
|
3 Participants
|
36 Participants
n=19 Participants
|
8 Participants
n=4 Participants
|
15 Participants
n=7 Participants
|
131 Participants
n=7 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
6 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
4 Participants
n=31 Participants
|
0 Participants
n=30 Participants
|
1 Participants
n=3 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=114 Participants
|
0 Participants
|
2 Participants
n=19 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=7 Participants
|
14 Participants
n=7 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
33 Participants
n=99 Participants
|
4 Participants
n=107 Participants
|
2 Participants
n=206 Participants
|
1 Participants
n=7 Participants
|
14 Participants
n=31 Participants
|
5 Participants
n=30 Participants
|
20 Participants
n=3 Participants
|
1 Participants
n=6 Participants
|
20 Participants
n=114 Participants
|
5 Participants
|
47 Participants
n=19 Participants
|
10 Participants
n=4 Participants
|
20 Participants
n=7 Participants
|
182 Participants
n=7 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=30 Participants
|
1 Participants
n=3 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=114 Participants
|
0 Participants
|
0 Participants
n=19 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=7 Participants
|
1 Participants
n=7 Participants
|
|
Race/Ethnicity, Customized
American Indian or Alaska Native
|
3 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
1 Participants
n=31 Participants
|
0 Participants
n=30 Participants
|
1 Participants
n=3 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=114 Participants
|
0 Participants
|
1 Participants
n=19 Participants
|
0 Participants
n=4 Participants
|
1 Participants
n=7 Participants
|
7 Participants
n=7 Participants
|
|
Race/Ethnicity, Customized
Asian
|
4 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
1 Participants
n=7 Participants
|
2 Participants
n=31 Participants
|
0 Participants
n=30 Participants
|
1 Participants
n=3 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=114 Participants
|
0 Participants
|
1 Participants
n=19 Participants
|
0 Participants
n=4 Participants
|
3 Participants
n=7 Participants
|
12 Participants
n=7 Participants
|
|
Race/Ethnicity, Customized
Black or African American
|
1 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=30 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=114 Participants
|
0 Participants
|
1 Participants
n=19 Participants
|
0 Participants
n=4 Participants
|
2 Participants
n=7 Participants
|
4 Participants
n=7 Participants
|
|
Race/Ethnicity, Customized
White
|
31 Participants
n=99 Participants
|
4 Participants
n=107 Participants
|
2 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
13 Participants
n=31 Participants
|
4 Participants
n=30 Participants
|
19 Participants
n=3 Participants
|
1 Participants
n=6 Participants
|
19 Participants
n=114 Participants
|
5 Participants
|
45 Participants
n=19 Participants
|
10 Participants
n=4 Participants
|
14 Participants
n=7 Participants
|
167 Participants
n=7 Participants
|
|
Race/Ethnicity, Customized
Mexican or Mexican American
|
0 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
2 Participants
n=31 Participants
|
0 Participants
n=30 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=114 Participants
|
0 Participants
|
1 Participants
n=19 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=7 Participants
|
4 Participants
n=7 Participants
|
|
Race/Ethnicity, Customized
White American Indian or Alaska Native
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=31 Participants
|
1 Participants
n=30 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=114 Participants
|
0 Participants
|
0 Participants
n=19 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=7 Participants
|
1 Participants
n=7 Participants
|
|
Race/Ethnicity, Customized
Unknown
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=30 Participants
|
1 Participants
n=3 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=114 Participants
|
0 Participants
|
0 Participants
n=19 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=7 Participants
|
1 Participants
n=7 Participants
|
|
Region of Enrollment
United States
|
39 participants
n=99 Participants
|
5 participants
n=107 Participants
|
2 participants
n=206 Participants
|
1 participants
n=7 Participants
|
18 participants
n=31 Participants
|
5 participants
n=30 Participants
|
22 participants
n=3 Participants
|
1 participants
n=6 Participants
|
20 participants
n=114 Participants
|
5 participants
|
49 participants
n=19 Participants
|
10 participants
n=4 Participants
|
20 participants
n=7 Participants
|
197 participants
n=7 Participants
|
PRIMARY outcome
Timeframe: Within 8 weeks of the study cell infusionDeath within 8 weeks of the study cell infusion thought to be definitely or probably related to CAR T cell therapy will be assessed.
Outcome measures
| Measure |
ALL (High Tumor Burden) Dose Level 1
n=39 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: high Dose level: 1 up to 2x105 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
ALL (High Tumor Burden) Dose Level 2
n=5 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: high Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
ALL (High Tumor Burden) Dose Level 3
n=2 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: high Dose level: 3 up to 2x107 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
ALL (Low Tumor Burden) Dose Level 1
n=1 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: low Dose level: 1 up to 2x105 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
ALL (Low Tumor Burden) Dose Level 2
n=18 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: high Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
CLL Dose Level 1
n=5 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: CLL Dose level: 1 up to 2x105 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
CLL Dose Level 2
n=22 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: CLL Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
CLL Dose Level 3
n=1 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: CLL Dose level: 3 up to 2x107 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
CLL (Ibrutinib) Dose Level 2
n=20 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: CLL (ibrutinib) Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
NHL Dose Level 1
n=5 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: NHL Dose level: 1 up to 2x105 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
NHL Dose Level 2
n=49 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: NHL Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
NHL Dose Level 3
n=10 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: NHL Dose level: 3 up to 2x107 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
NHL (Dose Dense) Dose Level 2
n=20 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: NHL Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Death Within 8 Weeks of the Study Cell Infusion Thought to be Definitely or Probably Related to Chimeric Antigen Receptor (CAR) T Cell Therapy
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
PRIMARY outcome
Timeframe: 30 daysOutcome will be reported as a count of participants that experienced a dose limiting toxicity on the study within 30 days post infusion.
Outcome measures
| Measure |
ALL (High Tumor Burden) Dose Level 1
n=39 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: high Dose level: 1 up to 2x105 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
ALL (High Tumor Burden) Dose Level 2
n=5 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: high Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
ALL (High Tumor Burden) Dose Level 3
n=2 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: high Dose level: 3 up to 2x107 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
ALL (Low Tumor Burden) Dose Level 1
n=1 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: low Dose level: 1 up to 2x105 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
ALL (Low Tumor Burden) Dose Level 2
n=18 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: high Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
CLL Dose Level 1
n=5 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: CLL Dose level: 1 up to 2x105 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
CLL Dose Level 2
n=22 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: CLL Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
CLL Dose Level 3
n=1 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: CLL Dose level: 3 up to 2x107 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
CLL (Ibrutinib) Dose Level 2
n=20 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: CLL (ibrutinib) Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
NHL Dose Level 1
n=5 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: NHL Dose level: 1 up to 2x105 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
NHL Dose Level 2
n=49 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: NHL Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
NHL Dose Level 3
n=10 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: NHL Dose level: 3 up to 2x107 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
NHL (Dose Dense) Dose Level 2
n=20 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: NHL Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dose Limiting Toxicities
|
3 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
2 Participants
|
0 Participants
|
4 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
3 Participants
|
0 Participants
|
PRIMARY outcome
Timeframe: Up to 1 yearOutcome will be reported as the count of patients per arm that experienced a complete response/partial response. Complete response (CR): CR per Lugano criteria for nodal disease and minimal residual disease (MRD)-negative CR by flow cytometry for marrow disease. Partial response (PR): \> 50% reduction of the sum of the products of the perpendicular diameters of marker lesions, no progression of any existing lesions, and no new lesions.
Outcome measures
| Measure |
ALL (High Tumor Burden) Dose Level 1
n=39 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: high Dose level: 1 up to 2x105 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
ALL (High Tumor Burden) Dose Level 2
n=5 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: high Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
ALL (High Tumor Burden) Dose Level 3
n=2 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: high Dose level: 3 up to 2x107 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
ALL (Low Tumor Burden) Dose Level 1
n=1 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: low Dose level: 1 up to 2x105 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
ALL (Low Tumor Burden) Dose Level 2
n=18 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: high Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
CLL Dose Level 1
n=5 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: CLL Dose level: 1 up to 2x105 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
CLL Dose Level 2
n=22 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: CLL Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
CLL Dose Level 3
n=1 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: CLL Dose level: 3 up to 2x107 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
CLL (Ibrutinib) Dose Level 2
n=20 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: CLL (ibrutinib) Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
NHL Dose Level 1
n=5 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: NHL Dose level: 1 up to 2x105 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
NHL Dose Level 2
n=49 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: NHL Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
NHL Dose Level 3
n=10 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: NHL Dose level: 3 up to 2x107 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
NHL (Dose Dense) Dose Level 2
n=20 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: NHL Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Objective Response Rate of Complete Response and Partial Response
|
32 Participants
|
5 Participants
|
1 Participants
|
1 Participants
|
18 Participants
|
4 Participants
|
16 Participants
|
1 Participants
|
12 Participants
|
2 Participants
|
28 Participants
|
4 Participants
|
10 Participants
|
PRIMARY outcome
Timeframe: Up to 1 yearOutcome will be reported as a count of patients who survived up to 1 year post infusion.
Outcome measures
| Measure |
ALL (High Tumor Burden) Dose Level 1
n=39 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: high Dose level: 1 up to 2x105 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
ALL (High Tumor Burden) Dose Level 2
n=5 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: high Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
ALL (High Tumor Burden) Dose Level 3
n=2 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: high Dose level: 3 up to 2x107 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
ALL (Low Tumor Burden) Dose Level 1
n=1 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: low Dose level: 1 up to 2x105 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
ALL (Low Tumor Burden) Dose Level 2
n=18 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: high Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
CLL Dose Level 1
n=5 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: CLL Dose level: 1 up to 2x105 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
CLL Dose Level 2
n=22 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: CLL Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
CLL Dose Level 3
n=1 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: CLL Dose level: 3 up to 2x107 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
CLL (Ibrutinib) Dose Level 2
n=20 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: CLL (ibrutinib) Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
NHL Dose Level 1
n=5 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: NHL Dose level: 1 up to 2x105 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
NHL Dose Level 2
n=49 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: NHL Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
NHL Dose Level 3
n=10 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: NHL Dose level: 3 up to 2x107 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
NHL (Dose Dense) Dose Level 2
n=20 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: NHL Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Survival
|
12 Participants
|
2 Participants
|
1 Participants
|
0 Participants
|
13 Participants
|
4 Participants
|
13 Participants
|
0 Participants
|
9 Participants
|
2 Participants
|
20 Participants
|
4 Participants
|
7 Participants
|
PRIMARY outcome
Timeframe: Up to 1 yearOutcome will be reported as the count of patients per arm that survived and whose disease did not progress in the 1 year timeframe post infusion.
Outcome measures
| Measure |
ALL (High Tumor Burden) Dose Level 1
n=39 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: high Dose level: 1 up to 2x105 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
ALL (High Tumor Burden) Dose Level 2
n=5 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: high Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
ALL (High Tumor Burden) Dose Level 3
n=2 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: high Dose level: 3 up to 2x107 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
ALL (Low Tumor Burden) Dose Level 1
n=1 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: low Dose level: 1 up to 2x105 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
ALL (Low Tumor Burden) Dose Level 2
n=18 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: high Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
CLL Dose Level 1
n=5 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: CLL Dose level: 1 up to 2x105 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
CLL Dose Level 2
n=22 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: CLL Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
CLL Dose Level 3
n=1 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: CLL Dose level: 3 up to 2x107 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
CLL (Ibrutinib) Dose Level 2
n=20 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: CLL (ibrutinib) Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
NHL Dose Level 1
n=5 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: NHL Dose level: 1 up to 2x105 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
NHL Dose Level 2
n=49 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: NHL Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
NHL Dose Level 3
n=10 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: NHL Dose level: 3 up to 2x107 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
NHL (Dose Dense) Dose Level 2
n=20 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: NHL Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Progression Free Survival
|
2 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
3 Participants
|
4 Participants
|
0 Participants
|
2 Participants
|
0 Participants
|
4 Participants
|
1 Participants
|
2 Participants
|
SECONDARY outcome
Timeframe: Up to day 365Population: Cohorts for this outcome are combined into disease type. The first row is a count of participants that were alive at the 1 year post infusion point within these cohorts. The second row is a count of participants who had CAR-T cells present at the 1 year follow up. This count has a lower number analyzed because it is out of the participants who had available CAR-T data at the 1 year followup timepoint.
Duration of persistence of adoptively transferred CD19 chimeric antigen receptor (CAR)-T cells. Outcome will be reported for each of the 3 cohorts on the study. Outcome data is both count of patients alive after 1 year and count of patients with CAR-T cells detected at 1 year.
Outcome measures
| Measure |
ALL (High Tumor Burden) Dose Level 1
n=65 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: high Dose level: 1 up to 2x105 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
ALL (High Tumor Burden) Dose Level 2
n=84 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: high Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
ALL (High Tumor Burden) Dose Level 3
n=48 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: high Dose level: 3 up to 2x107 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
ALL (Low Tumor Burden) Dose Level 1
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: low Dose level: 1 up to 2x105 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
ALL (Low Tumor Burden) Dose Level 2
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: high Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
CLL Dose Level 1
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: CLL Dose level: 1 up to 2x105 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
CLL Dose Level 2
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: CLL Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
CLL Dose Level 3
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: CLL Dose level: 3 up to 2x107 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
CLL (Ibrutinib) Dose Level 2
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: CLL (ibrutinib) Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
NHL Dose Level 1
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: NHL Dose level: 1 up to 2x105 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
NHL Dose Level 2
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: NHL Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
NHL Dose Level 3
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: NHL Dose level: 3 up to 2x107 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
NHL (Dose Dense) Dose Level 2
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: NHL Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Duration of Persistence of Adoptively Transferred CD19 Chimeric Antigen Receptor (CAR)-T Cells
Count of patients alive 1 year after CAR-T cell infusion
|
33 Participants
|
46 Participants
|
23 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Duration of Persistence of Adoptively Transferred CD19 Chimeric Antigen Receptor (CAR)-T Cells
Count of patients with CAR-T cells detected at 1 year
|
3 Participants
|
14 Participants
|
13 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Up to 1 yearPopulation: This outcome is split into arms by disease type. The first row is a count of participants out of those treated that had bone marrow disease involvement. The second row reports the count of participants with CAR-T cells detected in bone marrow at restaging. The total number analyzed for the count of participants with CAR-T cells detected in bone marrow at restaging is lower than the overall number analyzed because it is those who had available bone marrow data at the time of restaging.
Migration of adoptively transferred CD19 chimeric antigen receptor (CAR)-T cells. Outcome will be reported for each of the 3 cohorts on the study. Outcome data is both count of patients with bone marrow disease involvement and count of patients with CAR-T cells detected in bone marrow at restaging.
Outcome measures
| Measure |
ALL (High Tumor Burden) Dose Level 1
n=65 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: high Dose level: 1 up to 2x105 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
ALL (High Tumor Burden) Dose Level 2
n=84 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: high Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
ALL (High Tumor Burden) Dose Level 3
n=48 Participants
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: high Dose level: 3 up to 2x107 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
ALL (Low Tumor Burden) Dose Level 1
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: low Dose level: 1 up to 2x105 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
ALL (Low Tumor Burden) Dose Level 2
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: high Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
CLL Dose Level 1
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: CLL Dose level: 1 up to 2x105 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
CLL Dose Level 2
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: CLL Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
CLL Dose Level 3
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: CLL Dose level: 3 up to 2x107 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
CLL (Ibrutinib) Dose Level 2
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: CLL (ibrutinib) Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
NHL Dose Level 1
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: NHL Dose level: 1 up to 2x105 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
NHL Dose Level 2
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: NHL Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
NHL Dose Level 3
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: NHL Dose level: 3 up to 2x107 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
NHL (Dose Dense) Dose Level 2
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: NHL Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Migration of Adoptively Transferred CD19 Chimeric Antigen Receptor (CAR)-T Cells
Count of patients with bone marrow disease involvement
|
62 Participants
|
24 Participants
|
47 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Migration of Adoptively Transferred CD19 Chimeric Antigen Receptor (CAR)-T Cells
Count of patients with CAR-T cells detected in bone marrow at restaging
|
49 Participants
|
15 Participants
|
37 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
Adverse Events
ALL (High Tumor Burden) Dose Level 1
Serious events: 39 serious events
Other events: 39 other events
Deaths: 27 deaths
ALL (High Tumor Burden) Dose Level 2
Serious events: 5 serious events
Other events: 5 other events
Deaths: 3 deaths
ALL (High Tumor Burden) Dose Level 3
Serious events: 2 serious events
Other events: 2 other events
Deaths: 1 deaths
ALL (Low Tumor Burden) Dose Level 1
Serious events: 0 serious events
Other events: 1 other events
Deaths: 1 deaths
ALL (Low Tumor Burden) Dose Level 2
Serious events: 14 serious events
Other events: 18 other events
Deaths: 5 deaths
CLL Dose Level 1
Serious events: 5 serious events
Other events: 5 other events
Deaths: 1 deaths
CLL Dose Level 2
Serious events: 22 serious events
Other events: 22 other events
Deaths: 11 deaths
CLL Dose Level 3
Serious events: 1 serious events
Other events: 1 other events
Deaths: 1 deaths
CLL (Ibrutinib) Dose Level 2
Serious events: 20 serious events
Other events: 20 other events
Deaths: 11 deaths
NHL Dose Level 1
Serious events: 5 serious events
Other events: 5 other events
Deaths: 3 deaths
NHL Dose Level 2
Serious events: 49 serious events
Other events: 49 other events
Deaths: 32 deaths
NHL Dose Level 3
Serious events: 7 serious events
Other events: 10 other events
Deaths: 6 deaths
NHL (Dose Dense) Dose Level 2
Serious events: 20 serious events
Other events: 19 other events
Deaths: 13 deaths
Serious adverse events
| Measure |
ALL (High Tumor Burden) Dose Level 1
n=39 participants at risk
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: high Dose level: 1 up to 2x105 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
ALL (High Tumor Burden) Dose Level 2
n=5 participants at risk
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: high Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
ALL (High Tumor Burden) Dose Level 3
n=2 participants at risk
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: high Dose level: 3 up to 2x107 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
ALL (Low Tumor Burden) Dose Level 1
n=1 participants at risk
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: low Dose level: 1 up to 2x105 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
ALL (Low Tumor Burden) Dose Level 2
n=18 participants at risk
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: high Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
CLL Dose Level 1
n=5 participants at risk
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: CLL Dose level: 1 up to 2x105 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
CLL Dose Level 2
n=22 participants at risk
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: CLL Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
CLL Dose Level 3
n=1 participants at risk
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: CLL Dose level: 3 up to 2x107 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
CLL (Ibrutinib) Dose Level 2
n=20 participants at risk
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: CLL (ibrutinib) Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
NHL Dose Level 1
n=5 participants at risk
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: NHL Dose level: 1 up to 2x105 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
NHL Dose Level 2
n=49 participants at risk
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: NHL Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
NHL Dose Level 3
n=10 participants at risk
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: NHL Dose level: 3 up to 2x107 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
NHL (Dose Dense) Dose Level 2
n=20 participants at risk
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: NHL Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Hepatobiliary disorders
Hepatic failure
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
2.0%
1/49 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
1/10 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Immune system disorders
Cytokine release syndrome
|
25.6%
10/39 • Number of events 10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
5/5 • Number of events 5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
2/2 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
22.2%
4/18 • Number of events 4 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
1/5 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
36.4%
8/22 • Number of events 8 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
1/1 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
1/5 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
4.1%
2/49 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
50.0%
5/10 • Number of events 5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
2/20 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Blood and lymphatic system disorders
Disseminated intravascular coagulation
|
2.6%
1/39 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
1/10 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Blood and lymphatic system disorders
Febrile neutropenia
|
76.9%
30/39 • Number of events 42 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
5/5 • Number of events 5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
2/2 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
55.6%
10/18 • Number of events 11 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
80.0%
4/5 • Number of events 5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
95.5%
21/22 • Number of events 26 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
1/1 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
50.0%
10/20 • Number of events 10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
60.0%
3/5 • Number of events 3 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
55.1%
27/49 • Number of events 34 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
70.0%
7/10 • Number of events 10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
60.0%
12/20 • Number of events 13 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Blood and lymphatic system disorders
Lymph node pain
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.6%
1/18 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Cardiac disorders
Atrial fibrillation
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
2.0%
1/49 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
1/10 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Cardiac disorders
Cardiac arrest
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
4.5%
1/22 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
1/10 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Cardiac disorders
Heart failure
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
50.0%
1/2 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
1/10 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Cardiac disorders
Left ventricular systolic dysfunction
|
2.6%
1/39 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
4.5%
1/22 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Cardiac disorders
Pericardial tamponade
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
1/5 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
2.0%
1/49 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Cardiac disorders
Sick sinus syndrome
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
1/10 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Cardiac disorders
Sinus bradycardia
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
1/10 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Cardiac disorders
Sinus tachycardia
|
2.6%
1/39 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
2.0%
1/49 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
1/10 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Cardiac disorders
Supraventricular tachycardia
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
2.0%
1/49 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
2.0%
1/49 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Gastrointestinal disorders
Anal fistula
|
2.6%
1/39 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Gastrointestinal disorders
Colitis
|
2.6%
1/39 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Gastrointestinal disorders
Gastric hemorrhage
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
1/10 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
1/5 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Gastrointestinal disorders
Pancreatitis
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
2.0%
1/49 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
General disorders
Fever
|
5.1%
2/39 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
60.0%
3/5 • Number of events 3 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
50.0%
1/2 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
11.1%
2/18 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
18.2%
4/22 • Number of events 4 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
2.0%
1/49 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
30.0%
3/10 • Number of events 3 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
General disorders
General disorders and administration site conditions - Other, specify
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
4.5%
1/22 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
1/10 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
General disorders
Multi-organ failure
|
2.6%
1/39 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
50.0%
1/2 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
1/10 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
General disorders
Sudden death NOS
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Infections and infestations
Anorectal infection
|
2.6%
1/39 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
1/5 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Infections and infestations
Appendicitis
|
2.6%
1/39 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Infections and infestations
Bone infection
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
4.5%
1/22 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Infections and infestations
Catheter related infection
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.6%
1/18 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Infections and infestations
Infections and infestations - Other, specify
|
7.7%
3/39 • Number of events 3 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
1/5 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.6%
1/18 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
9.1%
2/22 • Number of events 8 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
1/10 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Infections and infestations
Lung infection
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.6%
1/18 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
1/5 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
9.1%
2/22 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
1/1 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Infections and infestations
Sepsis
|
5.1%
2/39 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Infections and infestations
Sinusitis
|
2.6%
1/39 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
4.5%
1/22 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
2.0%
1/49 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Investigations
White blood cell decreased
|
2.6%
1/39 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Metabolism and nutrition disorders
Tumor lysis syndrome
|
2.6%
1/39 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
50.0%
1/2 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Musculoskeletal and connective tissue disorders
Arthritis
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
4.5%
1/22 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Musculoskeletal and connective tissue disorders
Muscle weakness lower limb
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
2.0%
1/49 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumor pain
|
2.6%
1/39 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
2.0%
1/49 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Nervous system disorders
Central nervous system necrosis
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
1/5 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Nervous system disorders
Cognitive disturbance
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
50.0%
1/2 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Nervous system disorders
Depressed level of consciousness
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
60.0%
3/5 • Number of events 3 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
1/10 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Nervous system disorders
Dysarthria
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
4.5%
1/22 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Nervous system disorders
Dysphasia
|
2.6%
1/39 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Nervous system disorders
Edema cerebral
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.6%
1/18 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
4.5%
1/22 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Nervous system disorders
Encephalopathy
|
2.6%
1/39 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
60.0%
3/5 • Number of events 3 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
50.0%
1/2 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
11.1%
2/18 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
13.6%
3/22 • Number of events 3 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
6.1%
3/49 • Number of events 3 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
2/10 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
2/20 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Nervous system disorders
Nervous system disorders - Other, specify
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.6%
1/18 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Nervous system disorders
Seizure
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
60.0%
3/5 • Number of events 3 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Nervous system disorders
Somnolence
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.6%
1/18 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Nervous system disorders
Stroke
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.6%
1/18 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Psychiatric disorders
Delirium
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
50.0%
1/2 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.6%
1/18 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Psychiatric disorders
Depression
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
4.5%
1/22 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Psychiatric disorders
Suicide attempt
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Renal and urinary disorders
Acute kidney injury
|
2.6%
1/39 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
1/5 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
50.0%
1/2 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Renal and urinary disorders
Renal and urinary disorders - Other, specify
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Respiratory, thoracic and mediastinal disorders
Adult respiratory distress syndrome
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
1/5 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
4.5%
1/22 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnea
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
1/5 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Respiratory, thoracic and mediastinal disorders
Hiccups
|
2.6%
1/39 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
2.6%
1/39 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
50.0%
1/2 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.6%
1/18 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
4.5%
1/22 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
1/5 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Respiratory, thoracic and mediastinal disorders
Laryngeal edema
|
2.6%
1/39 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
1/5 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
2.0%
1/49 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary edema
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.6%
1/18 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
9.1%
2/22 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory failure
|
2.6%
1/39 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
40.0%
2/5 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
50.0%
1/2 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
4.5%
1/22 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
1/5 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
2/10 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Vascular disorders
Capillary leak syndrome
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
50.0%
1/2 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Vascular disorders
Hypotension
|
23.1%
9/39 • Number of events 9 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
5/5 • Number of events 5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
50.0%
1/2 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
16.7%
3/18 • Number of events 3 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
13.6%
3/22 • Number of events 3 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
1/1 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
12.2%
6/49 • Number of events 6 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
50.0%
5/10 • Number of events 5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
Other adverse events
| Measure |
ALL (High Tumor Burden) Dose Level 1
n=39 participants at risk
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: high Dose level: 1 up to 2x105 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
ALL (High Tumor Burden) Dose Level 2
n=5 participants at risk
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: high Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
ALL (High Tumor Burden) Dose Level 3
n=2 participants at risk
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: high Dose level: 3 up to 2x107 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
ALL (Low Tumor Burden) Dose Level 1
n=1 participants at risk
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: low Dose level: 1 up to 2x105 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
ALL (Low Tumor Burden) Dose Level 2
n=18 participants at risk
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: ALL Tumor Burden: high Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
CLL Dose Level 1
n=5 participants at risk
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: CLL Dose level: 1 up to 2x105 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
CLL Dose Level 2
n=22 participants at risk
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: CLL Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
CLL Dose Level 3
n=1 participants at risk
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: CLL Dose level: 3 up to 2x107 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
CLL (Ibrutinib) Dose Level 2
n=20 participants at risk
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: CLL (ibrutinib) Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
NHL Dose Level 1
n=5 participants at risk
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: NHL Dose level: 1 up to 2x105 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
NHL Dose Level 2
n=49 participants at risk
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: NHL Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
NHL Dose Level 3
n=10 participants at risk
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: NHL Dose level: 3 up to 2x107 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
NHL (Dose Dense) Dose Level 2
n=20 participants at risk
Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
Disease subgroup: NHL Dose level: 2 up to 2x106 EGFR+ cells/kg
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes: Given IV
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
General disorders
Localized edema
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
1/10 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
General disorders
Non-cardiac chest pain
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.6%
1/18 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Blood and lymphatic system disorders
Anemia
|
84.6%
33/39 • Number of events 44 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
80.0%
4/5 • Number of events 4 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
50.0%
1/2 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
1/1 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
66.7%
12/18 • Number of events 15 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
60.0%
3/5 • Number of events 6 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
86.4%
19/22 • Number of events 27 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
1/1 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
80.0%
16/20 • Number of events 19 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
80.0%
4/5 • Number of events 6 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
65.3%
32/49 • Number of events 46 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
60.0%
6/10 • Number of events 7 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
70.0%
14/20 • Number of events 20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Blood and lymphatic system disorders
Blood and lymphatic system disorders - Other, specify
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
11.1%
2/18 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Blood and lymphatic system disorders
Disseminated intravascular coagulation
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
4.5%
1/22 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Blood and lymphatic system disorders
Febrile neutropenia
|
7.7%
3/39 • Number of events 3 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.6%
1/18 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
4.5%
1/22 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
4/20 • Number of events 4 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
6.1%
3/49 • Number of events 3 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Blood and lymphatic system disorders
Leukocytosis
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
4.5%
1/22 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Cardiac disorders
Atrial fibrillation
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
1/5 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Cardiac disorders
Sinus bradycardia
|
2.6%
1/39 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
1/5 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Cardiac disorders
Sinus tachycardia
|
12.8%
5/39 • Number of events 6 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
80.0%
4/5 • Number of events 4 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
16.7%
3/18 • Number of events 3 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
1/5 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
1/1 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
1/5 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.2%
5/49 • Number of events 5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
1/10 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Ear and labyrinth disorders
Ear pain
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
8.2%
4/49 • Number of events 6 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
1/10 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Gastrointestinal disorders
Diarrhea
|
5.1%
2/39 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
1/5 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.6%
1/18 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
1/5 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
4.5%
1/22 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
2.0%
1/49 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
30.0%
3/10 • Number of events 3 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Gastrointestinal disorders
Hemorrhoidal hemorrhage
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
2.0%
1/49 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Gastrointestinal disorders
Lower gastrointestinal hemorrhage
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
2.0%
1/49 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
16.7%
3/18 • Number of events 4 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
1/10 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Gastrointestinal disorders
Oral pain
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Gastrointestinal disorders
Rectal pain
|
2.6%
1/39 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
General disorders
Chills
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
2.0%
1/49 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
General disorders
Edema limbs
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
1/1 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
2.0%
1/49 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
2/20 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
General disorders
Fatigue
|
5.1%
2/39 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
1/5 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
4.1%
2/49 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
1/10 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
General disorders
Fever
|
5.1%
2/39 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
1/5 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
4.5%
1/22 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
1/1 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
2.0%
1/49 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
2/20 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
General disorders
General disorders and administration site conditions - Other, specify
|
2.6%
1/39 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
4.5%
1/22 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Immune system disorders
Cytokine release syndrome
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
2.0%
1/49 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Infections and infestations
Anorectal infection
|
2.6%
1/39 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
2.0%
1/49 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Infections and infestations
Catheter related infection
|
7.7%
3/39 • Number of events 3 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.6%
1/18 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
2.0%
1/49 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Infections and infestations
Infections and infestations - Other, specify
|
7.7%
3/39 • Number of events 3 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
50.0%
1/2 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
2.0%
1/49 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
1/10 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Infections and infestations
Lung infection
|
5.1%
2/39 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Infections and infestations
Pancreas infection
|
2.6%
1/39 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Infections and infestations
Sinusitis
|
2.6%
1/39 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
1/5 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.6%
1/18 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
9.1%
2/22 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Infections and infestations
Skin infection
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
2.0%
1/49 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Infections and infestations
Upper respiratory infection
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
4.5%
1/22 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Infections and infestations
Urinary tract infection
|
5.1%
2/39 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Injury, poisoning and procedural complications
Vascular access complication
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
4.5%
1/22 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
2.0%
1/49 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
1/10 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Investigations
Activated partial thromboplastin time prolonged
|
20.5%
8/39 • Number of events 8 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
60.0%
3/5 • Number of events 3 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
50.0%
1/2 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.6%
1/18 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
40.0%
2/5 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
9.1%
2/22 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
1/5 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
4.1%
2/49 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
40.0%
4/10 • Number of events 4 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
2/20 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Investigations
Alanine aminotransferase increased
|
10.3%
4/39 • Number of events 4 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
40.0%
2/5 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
50.0%
1/2 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
40.0%
2/5 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
9.1%
2/22 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
2/20 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
1/5 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
2.0%
1/49 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
1/10 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Investigations
Alkaline phosphatase increased
|
5.1%
2/39 • Number of events 3 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.6%
1/18 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
4.1%
2/49 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Investigations
Aspartate aminotransferase increased
|
10.3%
4/39 • Number of events 4 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
60.0%
3/5 • Number of events 3 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
50.0%
1/2 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.6%
1/18 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
40.0%
2/5 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
22.7%
5/22 • Number of events 5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
2/20 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
2.0%
1/49 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
1/10 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Investigations
Blood bilirubin increased
|
2.6%
1/39 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
1/5 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
50.0%
1/2 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
40.0%
2/5 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
4.5%
1/22 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
1/1 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
4.1%
2/49 • Number of events 3 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
1/10 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
2/20 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Investigations
Cardiac troponin I increased
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
50.0%
1/2 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
2/10 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Investigations
CPK increased
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
50.0%
1/2 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Investigations
Creatinine increased
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
1/5 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
50.0%
1/2 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Investigations
Ejection fraction decreased
|
2.6%
1/39 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Investigations
Electrocardiogram QT corrected interval prolonged
|
5.1%
2/39 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
2.0%
1/49 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Investigations
Fibrinogen decreased
|
15.4%
6/39 • Number of events 6 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
1/5 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
1/5 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
9.1%
2/22 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
2/20 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
4.1%
2/49 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
1/10 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Investigations
GGT increased
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.6%
1/18 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Investigations
Lipase increased
|
2.6%
1/39 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Investigations
Lymphocyte count decreased
|
100.0%
39/39 • Number of events 58 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
5/5 • Number of events 5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
2/2 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
1/1 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
18/18 • Number of events 27 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
5/5 • Number of events 7 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
95.5%
21/22 • Number of events 30 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
1/1 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
20/20 • Number of events 27 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
5/5 • Number of events 8 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
98.0%
48/49 • Number of events 81 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
10/10 • Number of events 14 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
95.0%
19/20 • Number of events 38 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Investigations
Lymphocyte count increased
|
2.6%
1/39 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
9.1%
2/22 • Number of events 3 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
2.0%
1/49 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Investigations
Neutrophil count decreased
|
100.0%
39/39 • Number of events 59 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
5/5 • Number of events 5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
2/2 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
1/1 • Number of events 4 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
18/18 • Number of events 25 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
5/5 • Number of events 9 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
22/22 • Number of events 34 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
1/1 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
20/20 • Number of events 29 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
5/5 • Number of events 7 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
98.0%
48/49 • Number of events 68 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
10/10 • Number of events 13 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
95.0%
19/20 • Number of events 31 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Investigations
Platelet count decreased
|
74.4%
29/39 • Number of events 52 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
5/5 • Number of events 5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
2/2 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
1/1 • Number of events 3 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
72.2%
13/18 • Number of events 17 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
5/5 • Number of events 7 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
90.9%
20/22 • Number of events 28 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
1/1 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
75.0%
15/20 • Number of events 17 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
80.0%
4/5 • Number of events 6 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
63.3%
31/49 • Number of events 43 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
50.0%
5/10 • Number of events 6 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
55.0%
11/20 • Number of events 18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Investigations
Urine output decreased
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
50.0%
1/2 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Investigations
Weight gain
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
50.0%
1/2 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Investigations
White blood cell decreased
|
100.0%
39/39 • Number of events 56 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
5/5 • Number of events 5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
2/2 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
1/1 • Number of events 3 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
18/18 • Number of events 24 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
5/5 • Number of events 8 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
95.5%
21/22 • Number of events 31 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
1/1 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
20/20 • Number of events 29 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
5/5 • Number of events 7 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
95.9%
47/49 • Number of events 67 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
10/10 • Number of events 13 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
90.0%
18/20 • Number of events 28 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Metabolism and nutrition disorders
Acidosis
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
40.0%
2/5 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
50.0%
1/2 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
1/10 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Metabolism and nutrition disorders
Alkalosis
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
1/5 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
2/10 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Metabolism and nutrition disorders
Anorexia
|
5.1%
2/39 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.6%
1/18 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
1/5 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
4.5%
1/22 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
2.0%
1/49 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
30.0%
3/10 • Number of events 3 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Metabolism and nutrition disorders
Dehydration
|
2.6%
1/39 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Metabolism and nutrition disorders
Hypercalcemia
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
1/1 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Metabolism and nutrition disorders
Hyperglycemia
|
23.1%
9/39 • Number of events 12 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
1/1 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
16.7%
3/18 • Number of events 3 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
1/5 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
18.2%
4/22 • Number of events 5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
1/1 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
4/20 • Number of events 4 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
8.2%
4/49 • Number of events 5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
2/10 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
4/20 • Number of events 4 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Metabolism and nutrition disorders
Hyperkalemia
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
4.5%
1/22 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
1/10 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Metabolism and nutrition disorders
Hypermagnesemia
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
1/1 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Metabolism and nutrition disorders
Hyperuricemia
|
2.6%
1/39 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
50.0%
1/2 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
9.1%
2/22 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Metabolism and nutrition disorders
Hypoalbuminemia
|
5.1%
2/39 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
60.0%
3/5 • Number of events 3 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
4.5%
1/22 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
6.1%
3/49 • Number of events 3 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
1/10 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Metabolism and nutrition disorders
Hypocalcemia
|
5.1%
2/39 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
80.0%
4/5 • Number of events 4 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
2/2 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.6%
1/18 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
40.9%
9/22 • Number of events 9 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
4.1%
2/49 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
1/10 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Metabolism and nutrition disorders
Hypokalemia
|
12.8%
5/39 • Number of events 5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
40.0%
2/5 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
50.0%
1/2 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
22.2%
4/18 • Number of events 4 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
4.5%
1/22 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
2.0%
1/49 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
15.0%
3/20 • Number of events 3 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Metabolism and nutrition disorders
Hypomagnesemia
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.6%
1/18 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
2.0%
1/49 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Metabolism and nutrition disorders
Hyponatremia
|
17.9%
7/39 • Number of events 10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
5/5 • Number of events 5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
50.0%
1/2 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
50.0%
9/18 • Number of events 10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
60.0%
3/5 • Number of events 4 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
50.0%
11/22 • Number of events 12 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
1/1 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
4/20 • Number of events 4 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
40.0%
2/5 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
42.9%
21/49 • Number of events 22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
30.0%
3/10 • Number of events 4 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
35.0%
7/20 • Number of events 9 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Metabolism and nutrition disorders
Hypophosphatemia
|
38.5%
15/39 • Number of events 16 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
5/5 • Number of events 5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
2/2 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
33.3%
6/18 • Number of events 6 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
1/5 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
45.5%
10/22 • Number of events 11 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
1/1 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
25.0%
5/20 • Number of events 5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
28.6%
14/49 • Number of events 16 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
70.0%
7/10 • Number of events 8 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
25.0%
5/20 • Number of events 5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Metabolism and nutrition disorders
Tumor lysis syndrome
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
1/5 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
4.5%
1/22 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
1/1 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
2.6%
1/39 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
4.1%
2/49 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Musculoskeletal and connective tissue disorders
Bone pain
|
2.6%
1/39 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
4.1%
2/49 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Musculoskeletal and connective tissue disorders
Flank pain
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
2.0%
1/49 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Musculoskeletal and connective tissue disorders
Generalized muscle weakness
|
10.3%
4/39 • Number of events 4 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
40.0%
2/5 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
50.0%
1/2 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
1/5 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
1/1 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
2/20 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
4.1%
2/49 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
1/10 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Musculoskeletal and connective tissue disorders
Muscle weakness left-sided
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.6%
1/18 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
2.0%
1/49 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumor pain
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
2.0%
1/49 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Nervous system disorders
Ataxia
|
2.6%
1/39 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Nervous system disorders
Cognitive disturbance
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
4.5%
1/22 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
1/10 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Nervous system disorders
Depressed level of consciousness
|
2.6%
1/39 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Nervous system disorders
Dysarthria
|
2.6%
1/39 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
1/5 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Nervous system disorders
Dysphasia
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.6%
1/18 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
1/10 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
2/20 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Nervous system disorders
Encephalopathy
|
5.1%
2/39 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
40.0%
2/5 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
11.1%
2/18 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
18.2%
4/22 • Number of events 4 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
1/1 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
2/20 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
40.0%
2/5 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
4.1%
2/49 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
2/10 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Nervous system disorders
Headache
|
5.1%
2/39 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
22.2%
4/18 • Number of events 4 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
2/20 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
1/5 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
4.1%
2/49 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
1/10 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Nervous system disorders
Movements involuntary
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
1/5 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Nervous system disorders
Nystagmus
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
1/10 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Nervous system disorders
Peripheral motor neuropathy
|
2.6%
1/39 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
1/5 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
2.0%
1/49 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
1/10 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Nervous system disorders
Peripheral sensory neuropathy
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
2.0%
1/49 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Nervous system disorders
Somnolence
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
1/5 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Nervous system disorders
Syncope
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Nervous system disorders
Tremor
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
1/1 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
1/10 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Psychiatric disorders
Agitation
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
4.5%
1/22 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Psychiatric disorders
Delirium
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.6%
1/18 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Psychiatric disorders
Depression
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
2.0%
1/49 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Psychiatric disorders
Insomnia
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
1/1 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Psychiatric disorders
Personality change
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.6%
1/18 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Renal and urinary disorders
Acute kidney injury
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
1/1 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
1/10 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Renal and urinary disorders
Hematuria
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
40.0%
2/5 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
2.0%
1/49 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Renal and urinary disorders
Urinary incontinence
|
2.6%
1/39 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
40.0%
2/5 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
2.0%
1/49 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Reproductive system and breast disorders
Vaginal hemorrhage
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
1/5 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Respiratory, thoracic and mediastinal disorders
Apnea
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
1/5 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Respiratory, thoracic and mediastinal disorders
Aspiration
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.6%
1/18 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnea
|
10.3%
4/39 • Number of events 4 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
1/5 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
4.5%
1/22 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
1/1 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
6.1%
3/49 • Number of events 3 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
30.0%
3/10 • Number of events 3 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
20.5%
8/39 • Number of events 8 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
80.0%
4/5 • Number of events 4 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
1/5 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
36.4%
8/22 • Number of events 8 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
1/1 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
15.0%
3/20 • Number of events 3 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
12.2%
6/49 • Number of events 7 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
2/10 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
15.0%
3/20 • Number of events 3 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
1/5 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
4.5%
1/22 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
2.0%
1/49 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary edema
|
5.1%
2/39 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
9.1%
2/22 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
2.0%
1/49 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
5.0%
1/20 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Skin and subcutaneous tissue disorders
Rash acneiform
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
2.0%
1/49 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Skin and subcutaneous tissue disorders
Rash maculo-papular
|
7.7%
3/39 • Number of events 4 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
50.0%
1/2 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
18.2%
4/22 • Number of events 4 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Skin and subcutaneous tissue disorders
Skin ulceration
|
2.6%
1/39 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Social circumstances
Menopause
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
100.0%
1/1 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Vascular disorders
Hypertension
|
15.4%
6/39 • Number of events 6 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
40.0%
2/5 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
11.1%
2/18 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
40.0%
2/5 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
22.7%
5/22 • Number of events 8 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
35.0%
7/20 • Number of events 10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
1/5 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
16.3%
8/49 • Number of events 11 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
2/10 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
4/20 • Number of events 5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Vascular disorders
Hypotension
|
30.8%
12/39 • Number of events 12 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
50.0%
1/2 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
16.7%
3/18 • Number of events 4 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
1/5 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
27.3%
6/22 • Number of events 8 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
45.0%
9/20 • Number of events 9 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
40.0%
2/5 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
16.3%
8/49 • Number of events 10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
20.0%
2/10 • Number of events 3 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
15.0%
3/20 • Number of events 3 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Vascular disorders
Lymphedema
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
2.0%
1/49 • Number of events 1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
|
Vascular disorders
Thromboembolic event
|
0.00%
0/39 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/18 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/22 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/1 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
10.0%
2/20 • Number of events 2 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/5 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/49 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/10 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
0.00%
0/20 • Adverse events will be assessed up to 1 year for each patient following their infusion.
Adverse Events will be extracted from the patient record and assessed by the Principle Investigator for relation to treatment. AEs will beb graded in severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.03).
|
Additional Information
Dr. Jordan Gauthier
Fred Hutchinson Cancer Research Center
Phone: 206-667-2713
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place